NCT06930742

Brief Summary

The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are: Does Mindfulness-Enhanced Dual-Task Training improve the cognitive or motor function of participants? Can the combination of Dual-Task Training and Mindfulness achieve better effects? Researchers will compare 3 groups (Dual-Task Training + Mindfulness, Dual-Task Training, and conventional motor task training) to see if Dual-Task Training and Mindfulness works to treat PD-MCI. Participants will: Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 16, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

April 16, 2025

Status Verified

April 1, 2025

Enrollment Period

3 months

First QC Date

April 9, 2025

Last Update Submit

April 9, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a widely used neuropsychological tool for detecting mild cognitive impairment (MCI). It assesses multiple cognitive domains, including attention, executive function, memory, language, visuospatial ability, abstraction, calculation, and orientation. The total score is 30 points, with higher scores indicating better cognitive function.

    From enrollment to the end of treatment at 4 weeks

Study Arms (3)

MDT group

EXPERIMENTAL

Mindfulness-enhanced Dual-task Training

Device: Cognitive-Motor Dual-Task TrainingOther: Mindfulness Training

DT group

ACTIVE COMPARATOR

Dual-task Training

Device: Cognitive-Motor Dual-Task TrainingOther: Quiet Rest

ST group

ACTIVE COMPARATOR

Single-task Training

Device: Single-task TrainingOther: Quiet Rest

Interventions

Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach: Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks). Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks. Task difficulty is progressively adjusted based on participant performance.

DT groupMDT group

Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.

MDT group

Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.

ST group

Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.

DT groupST group

Eligibility Criteria

Age55 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: Between 55 and 75 years.
  • Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria.
  • Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5.
  • Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI).
  • Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening.
  • Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months.
  • Ambulatory Ability: Able to walk independently, with or without assistive devices.
  • Sensory Abilities: Adequate vision and hearing to comply with study procedures.
  • Informed Consent: Willingness to provide written informed consent and comply with study requirements.

You may not qualify if:

  • Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors.
  • Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia.
  • Substance Abuse: Recent history of drug or alcohol abuse.
  • Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes.
  • Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD).
  • Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function.
  • Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing Mingzhou Rehabilitation Hospital

Nanjing, Jiangsu, 210046, China

Location

MeSH Terms

Conditions

Cognitive DysfunctionParkinson Disease

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
technician in charge

Study Record Dates

First Submitted

April 9, 2025

First Posted

April 16, 2025

Study Start

May 1, 2025

Primary Completion

July 30, 2025

Study Completion

July 30, 2025

Last Updated

April 16, 2025

Record last verified: 2025-04

Locations